This is a working overview of fatty diacid, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-21 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Vascular changes cause some of the most severe clinical signs of MCTD. Adult MCTD patients had uncontrolled overexpression of endostatin and vascular endothelial growth factor (VEGF), two angiostatic and angiogenic factors. VEGF levels were higher in MCTD individuals who had pulmonary arterial hypertension and myositis, which may indicate a more severe course of disease.
titration Also titrimetry or volumetric analysis. A laboratory method of quantitative chemical analysis that is used to determine the concentration of an identified analyte. The procedure involves preparing a particular reagent as a standard solution of known concentration and volume (called the titrant or titrator) and allowing it to react with a solution of the analyte (called the titrand) to determine the latter's concentration.
{\displaystyle {\begin{aligned}K_{M}^{\prime }\ &{\stackrel {\mathrm {def} }{=}}\ {\frac {k_{3}}{k_{2}+k_{3}}}K_{M}={\frac {k_{3}}{k_{2}+k_{3}}}\cdot {\frac {k_{2}+k_{-1}}{k_{1}}}\\k_{cat}\ &{\stackrel {\mathrm {def} }{=}}\ {\dfrac {k_{3}k_{2}}{k_{2}+k_{3}}}\end{aligned}}}
Sources: en.wikipedia.org
== Further reading == Ball, Richard D.; Candido, Alessandro; Cruz-Martinez, Juan; Forte, Stefano; Giani, Tommaso; Hekhorn, Felix; Kudashkin, Kirill; Magni, Giacomo; Rojo, Juan (August 2022). "Evidence for intrinsic charm quarks in the proton". Nature. 608 (7923): 483–487. arXiv:2208.08372. Bibcode:2022Natur.608..483N. doi:10.1038/s41586-022-04998-2. ISSN 1476-4687. PMC 9385499. PMID 35978125. Gao, H.; Vanderhaeghen, M. (2022-01-21). "The proton charge radius". Reviews of Modern Physics. 94 (1) 015002. arXiv:2105.00571. Bibcode:2022RvMP...94a5002G. doi:10.1103/RevModPhys.94.015002. ISSN 0034-6861.
Pretargeting (imaging) is a tool for nuclear medicine and radiotherapy. Imaging studies require a high contrast of target to background. This can be provided by using a biomarker which has a high affinity and specificity for its target (e.g. an antibody).
doi:10.1016/S0733-8627(05)70156-5. PMID 11130936. Chantelau E., Schiffers T., Schutze J., Hansen B. (1997). "Effect of patient-selected intensive insulin therapy on quality of life". Patient Education and Counseling. 38 (2): 167–713. doi:10.1016/S0738-3991(96)00964-0. PMID 9128618.{{cite journal}}: CS1 maint: multiple names: authors list (link) Crawford L.M., Sinha R.N., Odell R.M., Comi R.J. (2000). "Efficacy of insulin pump therapy: mealtime delivery is the key factor". Endocrine Practice. 6 (3): 239–43. doi:10.4158/EP.6.3.239. PMID 11421538.{{cite journal}}: CS1 maint: multiple names: authors list (link) The DCCT Research Group. JAMA. 1997;227(5):374-4 Skyler J.S. Diabtes Technol Ther. 2000. The DCCT Research Group. Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. 1994. The DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. NEJM 2005; 353(25): 2643–2653. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus Diabetes Care 2001; 24: 1. Kaufman FR (2001). "A Pilot Study of the Continuous Glucose Monitoring System: Clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects". Diabetes Care. 24 (12): 2030–4. doi:10.2337/diacare.24.12.2030. PMID 11723078. Floyd J.C., Cornell R.G.; et al. (1993). "A prospective study identifying risk factors for discontinuance of insulin pump therapy".
At this time, the Selous Scouts comprised about 120 personnel and all of its officers were white. Black soldiers were offered bonuses that almost doubled their salary if they agreed to serve with the Selous Scouts. The unit was named after the British explorer Frederick Selous (1851–1917) and its motto was pamwe chete—a Shona phrase meaning "all together", "together only" or "forward together". The charter of the Selous Scouts directed them to "the clandestine elimination of terrorism both within and without the country". The name Selous Scouts had previously been attached to the Rhodesian Armoured Car Regiment of the Federal Army of Rhodesia and Nyasaland. The South African Police's Special Branch provided funding for the Selous Scouts. This formed part of the South African Government's extensive support for the Rhodesian counterinsurgency effort. Many South African Defence Force personnel served in the Selous Scouts between 1973 and 1979, including during operations in Rhodesia, Mozambique and Zambia. After the South African Government publicly withdrew the South African Police units which had been deployed to Rhodesia in 1975 SADF personnel continued to serve with the Selous Scouts. A witness who testified at the post-Apartheid South African Truth and Reconciliation Commission stated that the Selous Scouts were covertly funded by the South African Police and South African police officers also served in the unit.
Sources: en.wikipedia.org
Presence of AIDS with low pretreatment CD4 count, typically <100 cells/microL. An exception is in the setting of Mycobacterium tuberculosis infection, which can be reactivated with CD4 cells >200 cells/microL. Decrease in HIV-1 RNA levels from baseline or increase in CD4 count after starting ART No evidence of drug-resistant infection, bacterial superinfection, adverse drug reaction, patient non-adherence, or reduced serum drug levels (from drug-drug interactions or malabsorption). Clinical symptoms consistent with an inflammatory condition Temporal association between initiation of ART and symptom onset The differential diagnosis of IRIS is broad given its varied presentation. Conditions that can present similarly to IRIS are: adverse drug effects, progression of initial OI caused by medication resistance or patient non-adherence, and development of a new OI.
== Expression == Thy-1 expression varies between species. Amongst the cells reported to generally express Thy-1 are thymocytes (precursor of T cells in the thymus) & CD34(+) prothymocytes; neurons, mesenchymal stem cells, hematopoietic stem cells, NK cells, murine T-cells, endothelium (mainly in high endothelial venules or HEVs where diapedesis takes place), renal glomerular mesangial cells, circulating metastatic melanoma cells, follicular dendritic cells (FDC), a fraction of fibroblasts and myofibroblasts.
Fentanyl is contributing to an epidemic of synthetic opioid drug overdose deaths in the United States. From 2011 to 2021, overdose deaths involving prescription opioid (natural and semi-synthetic opioids and methadone) per year remained stable, while synthetic opioid (primarily fentanyl) associated overdose deaths per year increased from 2,600 overdoses to 70,601. Fentanyl was involved in the most drug overdose deaths in the United States in 2018. The United States National Forensic Laboratory estimates fentanyl reports by federal, state, and local forensic laboratories increased from 4,697 reports in 2014 to 117,045 reports in 2020. Fentanyl is often mixed, cut, or ingested alongside other drugs, including cocaine and heroin. Fentanyl has been reported in pill form, including pills mimicking pharmaceutical drugs such as oxycodone. Mixing with other drugs or disguising as a pharmaceutical makes it difficult to determine the correct treatment in the case of an overdose, resulting in more deaths. Emerging adulterants have further complicated the evolving fentanyl supply. In an attempt to reduce the number of overdoses from taking other drugs mixed with fentanyl, drug testing kits, strips, and labs are available.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.